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1222Influence of GST Gene Polymorphisms on the Clearance
of Intravenous Busulfan in Adult Patients Undergoing
Hematopoietic Cell Transplantation
Sung-Doo Kim,1 Je-Hwan Lee,1 Eun-Hye Hur,1 Jung-Hee Lee,1 Dae-Young Kim,1
Sung-Nam Lim,1 Yunsuk Choi,1 Hyeong-Seok Lim,2 Kyun-Seop Bae,2 Gyu-Jeong Noh,2
Sung-Cheol Yun,3 Sang Beom Han,4 Kyoo-Hyung Lee1Intravenous (i.v.) busulfan can produce a more consistent pharmacokinetic profile than oral formulations can,
but nonetheless, significant interpatient variability is evident.We investigated the influence of polymorphisms
of 3 GST isozyme genes (GSTA1, GSTM1, and GSTT1) on i.v. busulfan clearance. Fifty-eight adult patients who
received 3.2 mg/kg/day of busulfan as conditioning for hematopoietic cell transplantation were included in
this study. Stepwise multiple linear regression demonstrated that GSTA1 variant GSTA1*B (P 5 .004),
GSTM1/GSTT1 double-null genotype (P 5 .039), and actual body weight (P 5 .001) were significantly associ-
ated with lower clearance of i.v. busulfan. A trend test analyzing the overall effect of GST genotype on bu-
sulfan pharmacokinetics, combining GSTA1 gene polymorphism and the number of GSTM1- and GSTT-null
genotypes, showed a significant correlation between GST genotype and busulfan clearance (P 5 .001).
The clearance of i.v. busulfan was similar between patients with GSTA1*A/*A and GSTM1/GSTT1 double-
null genotypes and those with GSTA1*A/*B and GSTM1/GSTT1 double-positive genotypes. In conclusion,
a pharmacogenetic approach using GST gene polymorphisms may be valuable in optimizing the i.v. busulfan
dosage scheme. Our results also highlight the importance of including polygenic analyses and addressing
interactions among isozyme genes in pharmacogenetic studies.
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PharmacogeneticsINTRODUCTION
Hematopoietic cell transplantation (HCT) is a po-
tentially curative therapy of a range of hematologic dis-
eases [1-3]. Busulfan, a bifunctional DNA alkylating
agent, is commonly used in conditioning regimens for
HCT [3-5]. However, differences in busulfan
exposure attributable to variable pharmacokinetics are
associated with variations in clinical outcomes: high1Department of Hematology, 2Department of Clinical
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/$36.00
6/j.bbmt.2010.12.708busulfan exposure is associated with hepatic veno-
occlusive disease (VOD), whereas low busulfan levels
are associated with graft rejection or relapse [6-8].
Wide interpatient variability (10-fold or more) is
observed when oral busulfan is used, largely
attributable to unpredictable levels of intestinal
absorption and individual differences in first-pass
metabolism [9,10]. An intravenous (i.v.) formulation
of busulfan was developed to overcome the problems
associated with oral administration. Intravenous
busulfan offers more consistent dosing and
pharmacokinetic profiles than do oral formulations
[11].However, interpatient variability in the pharmaco-
kinetics of i.v. busulfan is still considerable [12,13] even
after correcting the busulfan dose for body size
parameters, including actual body weight (ABW),
ideal body weight (IBW), and body mass index (BMI),
all of which have been shown to correlate with
busulfan clearance [14]. Pharmacokinetics-guided bu-
sulfan dose adjustment is an attractive method because
blood concentrations aremeasurable, and there is inter-
patient variability and a relationship between busulfan
exposure and outcome in a narrow therapeutic index
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der the concentration-time curve (AUC) based onmea-
surements of the first-dose AUC are typically required
in 30% to 40%of patients [16].However, this approach
is limited by time, cost, expertise, and instrumentation.
Busulfan is metabolized mainly in the liver by
glutathione S-transferases (GSTs) [17,18] a family
of phase II detoxification enzymes that catalyze the
conjugation of glutathione to various xenobiotics
[19,20]. Human GSTs are divided into 3 main
families based on subcellular localization: cytosolic,
mitochondrial, and microsomal. The cytosolic family
is further subdivided into 7 classes: alpha, mu, omega,
pi, sigma, theta, and zeta [20]. Increasing number of
GST genes have been recognized to be polymorphic,
and certain alleles confer impaired catalytic activity
[19]. The alpha class of GSTs consists of 5 isoforms
(GSTA1-5) that are mostly expressed in the liver
[17,18]. The human GSTA1 gene has 3 linked single
nucleotide polymorphisms (SNPs) in the promoter
region, and 2 genotypes, GSTA1*A and GSTA1*B,
have been defined based on the linked
polymorphisms 2631 T.G, 2567 T.G, 269
C.T, and 252 G.A [21]. Homozygous GSTA1*B
status results in lower transcriptional activity and about
a 4-fold reduction in mean hepatic expression com-
pared to the homozygous GSTA1*A situation [21,22].
The mu class contains 5 GST isoforms (GSTM1-5),
and the theta class 2 (GSTT1 and GSTT2). GSTM1
and GSTT1 exhibit genetic polymorphisms among
human populations, and a large proportion of
individuals present with homozygous deletions
resulting in a null genotype characterized by a
complete lack of the respective protein [22]. The regula-
tion of GST expression also appears to differ according
to tissue and cell type. The liver contains high levels of
the GSTA1 isozyme; expression of GSTM1 and
GSTT1isozymes in liver tissueshasalsobeenconfirmed
[17,23-25]. Although busulfan is mainly metabolized
by GSTA1 in the liver, different GST isozymes may
play overlapping roles in busulfan metabolism, and
impaired activity of 1 GST isozyme may be
compensated by expression of other GSTs [17,26].
GST gene polymorphism may partly explain the
interpatient variability of busulfan clearance because
higher hepatic GST activity is associated with elevated
busulfan clearance and lower plasma busulfan concen-
trations [27]. Recently, attempts have been made to ex-
plain interpatient variability by examination of GST
gene polymorphisms, mostly in pediatric patients
[28-31]. But, current data regarding the association of
busulfan pharmacokinetics and GST polymorphisms
are conflicting in pediatric patients. There is only 1
small study in adult patients, regarding the
importance of GSTA1 polymorphism in determining
busulfan pharmacokinetics [32]. In this study, oral bu-
sulfan was administered. Until now, GSTA1, orGSTM1 has been reported to be associated with
busulfan pharmacokinetics [29,32-34]. GSTT1 has
been reported to have combined pharmacologic effects
with GSTM1 [35-38]. Thus, we investigated the
influence of polymorphisms in 3 GST genes, GSTA1,
GSTM1, and GSTT1, on the pharmacokinetics of i.v.
busulfan in adult patients undergoing HCT. We also
analyzed the combined effects of polymorphisms in
these 3 GST genes. The ultimate goal of the study was
to explore the utility of a pharmacogenetic approach
toward optimizing the dosage scheme of i.v. busulfan.PATIENTS AND METHODS
Patients
Sixty hematopoietic cell transplant recipients en-
rolled in our previous study on the pharmacokinetics
of i.v. busulfan were included in this pharmacogenetic
study [39]. All patients received 3.2 mg/kg/day i.v.
busulfan on the first day of conditioning therapy for
hematopoietic cell transplantation. This trial was ap-
proved by the institutional review board of the Asan
Medical Center, Seoul, Korea, and all the patients
gave written informed consent.
Transplantation Outline
Patients were randomized to receive i.v. busulfan
(3.2 mg/kg/day) either as a 4-times-daily regimen
(0.8 mg/kg over 2 hours, 4 times a day) or a once-
daily regimen (3.2 mg/kg over 3 hours, once a day).
All doses of busulfan were calculated using: (1)
ABW, if less than or equal to IBW; (2) IBW, if ABW
was greater than IBW, but within 120% of IBW; or
(3) IBW 1 (0.25  [ABW – IBW]), if ABW exceeded
IBW by .120%. Busulfan doses were not adjusted on
subsequent days.
All patients received 1 of the following condition-
ing regimens: i.v. busulfan (3.2 mg/kg/day on days27
to 24) plus i.v. cyclophosphamide (60 mg/kg/day on
days 23 and 22; n 5 15); i.v. busulfan (3.2 mg/kg/
day on days 27 and 26) and i.v. fludarabine (30 mg/
kg/day on days 27 to 22) plus varying doses of i.v.
anti-thymocyte globulin (ATG) (daily on days 24 to
22 or 21; n 5 33); or i.v. busulfan only (3.2 mg/kg/
day daily on days 26 to 23; n 5 2). No patient re-
ceived total-body irradiation (TBI). Phenytoin was
given for prevention of seizure from the day before
the first dose of busulfan to the day after the last
dose of busulfan. Nonchemotherapeutic concomitant
medications including antiemetics and hydration
were used per institutional guidelines in all patients.
Pharmacokinetic Studies
Blood samples (5 mL) were obtained from all pat-
ents at 5 time points for pharmacokinetic studies. In
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ples were drawn at 2.5, 3, 4, 5, and 6 hours after the
start of infusion; in those receiving once-daily busul-
fan, samples were drawn 3.5, 5, 6, 7, and 22 hours after
the start of the infusion. Blood samples, collected in
vacutainer tubes (BD Vacutainer, Franklin Lakes,
NJ) containing sodium heparin, were centrifuged
(2000  g) for 10 minutes at 4C, and the separated
plasma samples were stored at 240C until assay.
Plasma busulfan concentrations were quantified
using high-performance liquid chromatography
(HPLC) with tandem mass spectrometry (LC-MS/
MS) on an API 3000 triple-quadruple mass spectrom-
eter equipped with an electrospray ion source (MDS
SCIEX, South San Francisco, CA). In brief, an aliquot
of the sample (20 mL) was delivered into the electro-
spray ion source via anHPLC system (Agilent 1100 se-
ries, Agilent Technologies Inc., Santa Clara, CA) with
a C18 Capcell Pak MG column (2.0  50 mm, 3.0-mm
particle size). Linear calibration curves were estab-
lished over a range of busulfan concentrations from
30 to 6000 ng/mL; correlation coefficients were
.0.998 in all cases. The limit of quantification for bu-
sulfan was 30 ng/mL. The precision of intra- and in-
terday measurements for all analytes was within
\12.5%. Busulfan clearance was determined based
on a 1-compartment model using WinNonlin v5.0.1
(Pharsight Corporation, Mountain View, CA). Busul-
fan AUC per dose was calculated by dividing the drug
dose by the busulfan plasma clearance estimate.Identification of GSTA1, GSTM1, and GSTT1
Genotypes
For pretransplant genotype identification, geno-
mic DNA was isolated from peripheral blood lympho-
cytes using a genomic DNA extraction kit (Qiagen,
Chatsworth, CA). For genotyping of GSTA1
(GSTA1*A and GSTA1*B), the 269 C.T variation
in the promoter region of GSTA1 was analyzed using
the polymerase chain reaction (PCR) followed by
restriction fragment-length polymorphism analysis,
as previously described [40,41]. It was previously
shown that this SNP is in complete linkage
disequilibrium with 2631 T.G, 2567 T.G, and
252 G.A [21]. The promoter region of the GSTA1
gene was amplified with the forward primer GSTA1-
F (50-TGT TGA TTG TTT GCC TGA AAT T-30)
and the reverse primers GSTA1-R1 (50-GTT AAA
CGC TGT CAG CCG TCC T-30) and GSTA1-R2
(50-TTT GTT AAA TGC TGT CAC CTT TGT-
30). The PCR mixture contained 30 ng of DNA tem-
plate, 0.1 mg of each primer (100 pmol), and 5 premix
buffer (GeneChem Inc., Daejeon, Korea). PCR condi-
tions were as follows: initial denaturation at 95C for
10 minutes, 35 cycles of denaturation at 96C for 1
minute, annealing at 55C for 1 minute, and extensionat 72C for 1 minute, followed by a final extension at
72C for 6minutes. After amplification, PCR products
were digested with 10 U of the restriction endonucle-
ase EarI by incubating at 37C for 12 hours.
Homozygous deletions of GSTM1 and GSTT1
were detected using a PCR technique, as described
previously [42]. b-Actin was used as an internal con-
trol. PCR was carried out in a 50-mL reaction mixture
containing 30 ng of DNA template, 5 premix buffer
(GeneChem Inc.), and 0.1 mg of the following primer
pairs: GSTM1, 50-GAA CTC CCT GAA AAG CTA
AAG C-30 (forward) and 50-GTT GGG CTC AAA
TAT ACG GTG G-30 (reverse), which yield a 215-
bp fragment; GSTT1, 50-TCA CCG GAT CAT
GGC CAG CA-30 (forward) and 50-TTC CTT ACT
GGT CCT CAC ATC TC-30 (reverse), which yield
a 480-bp fragment; and b-actin, 50-GCC CTC TGC
TAA CAA GTC CTA C-30 (forward) and 50-GCC
CTA AAA AGA AAA TCC CCA ATC-30 (reverse),
which yield a 345-bp fragment. Amplification condi-
tions consisted of initial denaturation at 95C for 12
minutes, 35 cycles of denaturation at 94C for 1 min-
ute, annealing at 62C for 1 minute, and extension at
72C for 1 minute, followed by a final extension at
72C for 10 minutes. Genotype assignments were
made based on electrophoretic analyses of amplified
products in 3.5% agarose gels. Cases where appropri-
ate PCR products for GSTM1 or GSTT1 were absent
and b-actin was present were considered a null geno-
type (ie, homozygous deletion of GSTM1 or GSTT1).Statistical Analysis
Descriptive statistics, including means and stan-
dard deviations, and minimum, median, and maximum
values, were applied as appropriate. The chi-square
test was used to assess deviation of GSTA1 allele fre-
quency fromHardy-Weinberg equilibrium. Categoric
variables were compared using chi-square or Fisher’s
exact tests, and continuous variables were compared
using Student’s t-test.We used Spearman’s correlation
coefficient to test relationships between the number of
GSTM1- and GSTT1-null genotypes and busulfan
pharmacokinetics. A logarithmic transformation of
the pharmacokinetic variables (clearance and AUC)
was performed to stabilize the models.
Busulfan clearance was selected as representative
of interpatient variability of the busulfan pharmacoki-
netics rather than AUC because 2 different dosage reg-
imens (once daily and 4 times daily) were used in our
study. AUC was evaluated as a secondary parameter.
To select candidate variables for the multiple regres-
sion model of busulfan pharmacokinetics (clearance
and AUC), we initially examined the individual effects
of demographic data (age, gender, ABW, BMI,
and height), preconditioning laboratory data (serum
total bilirubin, aspartate aminotransferase, alanine
Table 1. Patients’ Demographics and Preconditioning Labo-
ratory Data
Characteristic Number of Patients (Total: 58)
Sex, male versus female 37 (63.8%) versus 21 (36.2%)
Age, year, median (range) 35.5 (16-58)
Diagnosis
AML 33 (56.9%)
ALL 6 (10.3%)
CML 8 (13.8%)
MDS 8 (13.8%)
MPD 2 (3.4%)
PNH 1 (1.7%)
Type of graft donor
HLA-matched sibling 29 (50.0%)
HLA haploidentical family 6 (10.3%)
Unrelated volunteer 21 (36.2%)
Autologous 2 (3.4%)
Conditioning regimen
Busulfan-cyclophosphamide 23 (39.7%)
Busulfan-fludarabine-ATG 33 (56.9%)
Busulfan 2 (3.4%)
ABW, kg; median (range) 64.0 (53.0-116.0)
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(presence of GSTA1*B genotype or number of
GSTM1- andGSTT1-null genotypes), and dosing reg-
imen (a 4-times-daily dosing versus a once-daily dos-
ing). Variables that were associated (P \ .10) with
busulfan pharmacokinetics and genetic variables were
considered further in a stepwise multiple linear regres-
sion model. Linear regression analysis was used to test
the correlation of combinations of the 3 GST geno-
types with busulfan pharmacokinetics. A trend test
for allele dose-effect relationships of the GST geno-
types was performed using the presence of GSTA1*B
genotype and GSTM1/GSTT1-null genotype (the
number of GSTM1- and GSTT1-null genotypes),
which were entered as ordered categoric variables.
P values\.05 were considered statistically signifi-
cant. Statistical analyses were carried out using the
SPSS package (version 14.0, SPSS, Chicago, IL).Height, cm; median (range) 168.1 (146.0-183.0)
Hemoglobin, g/dL; median (range) 10.7 (6.5-14.8)
Total leukocytes, 103/mL; median
(range)
4.0 (0.6-9.6)
Platelets, 103/mL; median (range) 127.5 (11.0-347.0)
Aspartate aminotransferase, IU/L;
median (range)
21.5 (12-77)
Alanine aminotransferase, IU/L;
median (range)
23.5 (7-231)
Total bilirubin, mg/dL; median (range) 0.8 (0.4-3.1)
Serum creatinine, mg/dL; median
(range)
0.8 (0.4-1.5)
AML indicates acute myeloid leukemia or acute mixed lineage leukemia;
ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia;
MPD, myeloproliferative disease; PNH, paroxysmal nocturnal hemoglo-
binuria; ATG, anti-thymocyte globulin.RESULTS
Patient Characteristics
GST polymorphisms were determined in 58 of the
60 hematopoietic cell transplant recipients enrolled in
our previous study [39]. Lack of sufficient DNA pre-
vented genotype analysis of 2 patients. Patient demo-
graphics and preconditioning laboratory data are
shown in Table 1. Acute leukemia, observed in 56.9%
of patients, was the most common underlying disease
indication for HCT. All but 2 patients received alloge-
neic HCT. The hematopoietic cell graft donor was an
HLA-matched sibling in half of patients. Bonemarrow
was used in 34 patients (58.6%), and granulocyte col-
ony-stimulating factor (G-CSF)–mobilized peripheral
blood mononuclear cells in 24 (41.4%).
Frequencies of GST Genotypes
Fourteen of the 58 patients (24.1%) were heterozy-
gous for GSTA1*B (GSTA1*A/*B) (Table 2). NoTable 2. Genotype Distribution of GSTA1, GSTM1, and GSTT1, and
Recipients
Parameter n (%) Age, years
GSTA1 genotype
*A/*A 44 (75.9) 37.1 ± 10.9
*A/*B 14 (24.1) 35.2 ± 11.7
GSTM1 genotype
Present 33 (56.9) 37.4 ± 10.0
Null 25 (43.1) 35.7 ± 12.4
GSTT1 genotype
Present 24 (41.4) 35.9 ± 9.3
Null 34 (58.6) 37.2 ± 12.2
GSTM1/GSTT1-null genotype
Neither 12 (20.7) 39.3 ± 8.9
Either 33 (56.9) 34.9 ± 10.1
Both 13 (22.4) 38.7 ± 14.7
GSTM1/GSTT1-null genotype indicates number of GSTM1- and GSTT1-null gen
Data are presented as number and percent, or mean 6 SD, as appropriate (†patient was homozygous forGSTA1*B (GSTA1*B/*B).
The allele frequency of the GSTA1 genotype was in
Hardy-Weinberg equilibrium (c2 5 1.09, P 5 .30).
TheGSTM1-null genotype was detected in 25 patients
(43%) and theGSTT1-null genotype in 34 (59%). The
baseline characteristics of patients were not signifi-
cantly different among GST genotypes, except for fe-
male predominance in patients with the GSTA1*A/*B
genotype (P 5 .023).Patient Characteristics of 58 Hematopoietic Cell Transplant
Female, n (%) Weight, kg Cr, mg/dL
12 (27.3)† 66.8 ± 12.0 0.86 ± 0.21
9 (64.3)† 66.7 ± 9.5 0.74 ± 0.24
13 (39.4) 66.7 ± 12.6 0.88 ± 0.24
8 (32.0) 66.8 ± 9.8 0.78 ± 0.19
8 (33.3) 65.3 ± 8.9 0.78 ± 0.16
13 (38.2) 67.8 ± 12.9 0.87 ± 0.25
4 (33.3) 66.1 ± 9.5 0.83 ± 0.20
13 (39.4) 66.1 ± 12.4 0.85 ± 0.23
4 (30.8) 69.0 ± 10.7 0.82 ± 0.24
otypes; SD, standard deviation; Cr, serum creatinine.
P 5 .023).
Table 3. Association between GST Gene Polymorphisms and Pharmacokinetic Parameters of i.v. Busulfan
Parameter n (%) Clearance mL/min/kg† P AUC, mM$min/mg P
GSTA1 genotype
*A/*A 44 (75.9) 2.03 ± 0.35 .015 31.53 ± 5.56 .039
*A/*B 14 (24.1) 1.79 ± 0.30 35.42 ± 6.59
GSTM1 genotype
Present 33 (56.9) 2.01 ± 0.39 .382 31.93 ± 6.68 .340
Null 25 (43.1) 1.92 ± 0.28 33.18 ± 5.01
GSTT1 genotype
Present 24 (41.4) 2.05 ± 0.29 .086 31.49 ± 5.12 .355
Null 34 (58.6) 1.92 ± 0.38 33.16 ± 6.54
GSTM1/GSTT1-null genotype
Neither 12 (20.7) 2.08 ± 0.30 .048 30.37 ± 4.30 .097
Either 33 (56.9) 1.99 ± .038 32.75 ± 6.96
Both 13 (22.4) 1.82 ± 0.25 33.70 ± 4.34
AUC indicates dose-normalized area under the plasma concentration-time curve; GSTM1/GSTT1-null genotype, number of GSTM1- and GSTT1-null ge-
notypes; SD, standard deviation.
Data are presented as number and percent, or mean 6 SD, as appropriate.
†Total plasma clearance.
1226 Biol Blood Marrow Transplant 17:1222-1230, 2011S.-D. Kim et al.Factors Associated with Busulfan Clearance
Despite adjusting busulfan dosing with respect to
body weight, busulfan clearance varied by about 2-
fold among patients (range: 1.41-2.78 mL/min; me-
dian, 1.89 mL/min). Associations between GST gene
polymorphisms and the pharmacokinetic parameters
of busulfan are listed in Table 3 and depicted in
Figure 1. Carriers of GSTA1*B showed significantly
lower busulfan clearance than did GSTA1*A/*A car-
riers (P 5 .015). Although neither GSTM1- nor
GSTT1-null genotypes alone were significantly associ-
ated with busulfan clearance (P 5 .382 and P 5 .086,
respectively), the GSTM1/GSTT1-null genotype (ie,1. 0 
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Figure 1. Comparison of busulfan clearance distribution according to GST gen
GSTM1, (C) GSTT1, and (D) GSTM1/GSTT1-null genotype (ie, the number of Gthe number of GSTM1- and GSTT1-null genotypes)
was significantly associated with busulfan clearance
(P 5 .048). Among demographic and preconditioning
laboratory variables, ABW (R52.420; P5 .001) and
BMI (R 5 2.394, P 5 .002) were statistically signifi-
cant factors with respect to busulfan clearance (data
not shown). Because ABW and BMI were highly inter-
correlated (R 5 .805, P\ .001), only ABW was in-
cluded as a body size measure in the multivariate
models. Gender was not significantly associated with
busulfan clearance (P 5 .950).
Thus, the GSTA1 genotype, the GSTM1/GSTT1
genotype combination, and ABW were included in1. 0 
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STM1- and GSTT1-null genotypes).
Table 4. Multiple Linear Regression Model for Prediction of Clearance of i.v. Busulfan
Variable Regression Coefficient 95% CI Partial R2 (%) P
GSTA1 genotype* 20.058 20.097 to 20.020 10.1 .004
GSTM1/GSTT1 genotype† 20.027 20.052 to 20.001 5.5 .039
Actual body weight (in kg) 20.003 20.004 to 20.001 17.6 .001
95% CI indicates 95% confidence interval for regression coefficient.
*Coded as 0 if *A/*A and 1 if *A/*B.
†Number of GSTM1- and GSTT1-null genotypes.
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(Table 4). After stepwise regression, the GSTA1 geno-
type, the GSTM1/GSTT1 genotype combination, and
ABW were all retained in the final model (R2 5 .333,
P\ .001), which explained 33.3% of total variability.
Notably, the predictive power of GST genotypes
(15.6%) was comparable to that of ABW (17.6%).
With respect to busulfan AUC, the GSTA1 geno-
type (P5 .039), the GSTM1/GSTT1 genotype combi-
nation (P 5 .097), ABW (R 5 2.355, P 5 .006), BMI
(R 5 2.245, P 5 .064), gender (P 5 .001), serum cre-
atinine (R52.303, P5 .021), and bilirubin level (R5
2.218, P 5 .099) were significantly or marginally
correlated. A multivariate model that included GST
genotypes, ABW, gender, creatinine, and bilirubin
showed that the GSTA1 genotype (P 5 .021), the
GSTM1/GSTT1 genotype combination (P 5 .036),
and ABW (P\ .001) were independent predictors of
the busulfan AUC (R2 5 .351, P\ .001), as was the
case with busulfan clearance.2. 5 
3. 0 
i n
/ kg
 ) Impact of the Combination of GST
Polymorphisms on Busulfan Clearance
We analyzed the overall effect of GST gene poly-
morphisms on busulfan pharmacokinetics by combin-
ing GSTA1 gene polymorphism and the number
of GSTM1- and GSTT1-null genotypes (Table 5). A
trend test showed that even after adjusting for ABW,
GST genotypes were significantly correlated with bu-
sulfan clearance (Figure 2, P 5 .001). A similar trend
was also observed in the busulfan AUC after inclusion
of ABW in the regression model (P 5 .002).Table 5. Clearance of i.v. Busulfan According to Combined
GST Gene Polymorphism
GSTA1 GSTM1/GSTT1-null No.
Clearance (mL/min/kg)†
mean ± SD 95% CI
*A/*A Neither 7 2.17 ± 0.31 1.62-2.89
Either 28 2.03 ± 0.37 1.50-2.67
Both 9 1.91 ± 0.26 1.42-2.53
*A/*B Neither 5 1.95 ± 0.25 1.33-2.38
Either 5 1.75 ± 0.40 1.35-2.44
Both 4 1.63 ± 0.06 1.21-2.20
GSTM1/GSTT1-null indicates number of GSTM1- and GSTT1-null geno-
types; SD, standard deviation; 95% CI, 95% confidence interval for re-
gression coefficient.
†P 5 .001.DISCUSSION
The pharmacogenetic evaluation of genes involved
in drug pharmacokinetics has been suggested to be an
efficient method for individualizing drug therapy,
which may lead to improved efficacy or reduced drug
toxicity [43]. The variability in busulfan pharmacoki-
netics has hampered the effectiveness of busulfan-
based high-dose conditioning therapy for HCT. Use
of an i.v. busulfan formulation reduces, but does not
eliminate, interpatient variability in busulfan pharma-
cokinetics.
Recently, GST gene polymorphisms have been
recognized to have a significant role as a determinant
of interpatient variability in busulfan pharmacokinet-
ics, mostly in pediatric patients. Three such studies an-
alyzed the impact of polymorphisms in GST genes,
including GSTA1, GSTM1, GSTP1, and/or GSTT1,
on the pharmacokinetics of i.v. busulfan [28-30].
Two of the cited studies found a significant
correlation between GSTA1 polymorphic genotype
and the clearance of i.v. busulfan [28,29], whereas the
other reported no correlation between any GST
gene polymorphism and the pharmacokinetics of i.v.
busulfan [30]. A study of 12 Japanese adult patients
who had received oral busulfan also reported that the1. 0 
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Figure 2. Clearance of i.v. busulfan according to GST gene polymor-
phism. Horizontal lines indicate the means of each group. Busulfan clear-
ance was grouped by GSTA1 genotype and GSTM1/GSTT1-null genotype
(ie, the number of GSTM1- and GSTT1-null genotypes).
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[32]. Another pediatric study that analyzed polymor-
phisms of GSTA1, GSTM1, and GSTP1 genes found
that only the GSTM1 polymorphism was associated
with the pharmacokinetics of i.v. busulfan [34].
The reason for these discrepancies in the reported
impact of GST gene polymorphisms on the pharmaco-
kinetics of busulfan is not clear, but may include diffi-
culties in interpreting these relationships, differences
in study population, sample size, and GST isozymes
tested. Pharmacokinetics of busulfan seems to be influ-
enced by a particular combination of GST genotypes.
In fact, we observed a significant correlation between
pharmacokinetics of busulfan and the GSTM1/
GSTT1 genotype combination, although neither
GSTM1 nor GSTT1 alone were significantly corre-
lated with i.v. busulfan clearance (Tables 3 and 4).
The biochemical basis for this combined gene effect
is not clear, but most drug effects are determined by
interplay among several gene products that influence
pharmacokinetics and pharmacodynamics [44,45].
Thus, pharmacogenetics and pharmacogenomics are
increasingly being applied to identify polygenic
determinants of drug effects. Understanding the
role of different combinations of genotypes on
pharmacokinetics of busulfan is relevant in particular
when the complex network of metabolic pathway is
considered. Until now, this polygenic approach has
also been employed in epidemiologic studies to study
the role of GSTM1 and GSTT1 polymorphisms in
cancer. These studies have shown that GSTM1 and
GSTT1 double-null genotypes tend to have negative
prognostic values in various cancers, including acute
myeloid leukemia, childhood B-precursor acute
lymphoblastic leukemia, and lymphoma [35-37].
Furthermore, in 1 pharmacogenetic study designed
to predict drug-induced liver injury, only GSTM1
and GSTT1 double-null genotypes were found to
play a role in determining such susceptibility, regard-
less of the drug involved [38]. In addition, ethnic
differences in the frequencies of GST polymorphic ge-
notypes have been reported and may contribute to the
variation seen. The frequency of GSTM1- and
GSTT1-null genotypes was similar to those found in
previously studied Asian population. In the present
study, the GSTM1-null genotype was found in 57%
of the study population compared with frequencies
of 48% to 56% in Asians, 34% to 58% in Caucasians,
and 17% to 47% in Africans [46-49]. The frequency of
the GSTT1-null genotype was 41% in our study,
compared with 45% to 64% in Asians, 15% to 22%
in Caucasians, and 20% to 38% in Africans
[47,49,50]. The minor allele frequency of GSTA1 in
our study (12%) was also similar to that found in
previously studied Asian population (12%-14%),
compared with that in Caucasians (34-36%)
[28,29,32,51].In our patients, the GSTA1*A/*B genotype was
more frequent in women than in men. As such gender
differences have not been observed in previous studies,
this finding may be insignificant and relate to the lim-
ited sample size [51-53]. Busulfan clearance was
independent of gender in univariate analysis, and the
multiple regression model to predict busulfan
clearance was not influenced by the gender factor.
Thus, we presented the final multiple regression
model without including gender as a covariate, which
coincides with other population pharmacokinetic
studies [28-30].
A shortcoming of most studies on the biological ef-
fects of GSTM1 and GSTT1 genotypes, including our
study, is that individualswhoare heterozygousorhomo-
zygous for the functional alleles are not distinguished,
rather being grouped together. As a consequence, the
significance of heterozygosity for wild-type GSTM1 or
GSTT1 has seldom been addressed [19].
Our investigation of the relationship between
GSTA1, GSTM1, and GSTT1 genotypes, and i.v. bu-
sulfan pharmacokinetics in adult HCT recipients,
showed that GST gene polymorphisms significantly
affected the pharmacokinetics of i.v. busulfan and
were independent factors underlying interpatient
variation in pharmacokinetic parameters. These poly-
morphic GST enzymes would have reduced excretion
of busulfan (and hence, decreased clearance) because
reduced GST activities cause lesser degrees of water
solubility of busulfan. Of the GST gene polymor-
phisms tested, the GSTA1 genotype was the most
important in predicting busulfan clearance and dose-
adjusted AUC. Patients of GSTA1*B genotype had
significantly reducedbusulfanclearance,whichwas con-
sistent with previous reports [28,29,32] and is consistent
with the fact thatGSTA1 is themain enzyme involved in
busulfanmetabolism [17,18]. In the present study, linear
regression models demonstrated that both the GSTA1
genotype and the combination of GSTM1/GSTT1
genotypes were independently associated with the
clearance and dose-normalized AUC of i.v. busulfan.
These results suggest overlapping roles for different
GST genes in busulfan metabolism, and prompted us
to analyze the overall effect of different GST genes
(Table 5). The clearance of i.v. busulfan was similar be-
tween patients with GSTA1*A/*A and GSTM1/GSTT1
double-null genotypes and those withGSTA1*A/*B and
GSTM1/GSTT1 double-positive genotypes. Our study
showed the importance of interactions among isozyme
genes, suggesting that expression of GSTM1/GSTT1
may compensate for impaired activity of GSTA1 in
the liver metabolism of busulfan. To the best of our
knowledge, this is the first comprehensive GST phar-
macogenetic analysis to assess the pharmacokinetics of
i.v. busulfan in adult patients and to demonstrate the
combined effect of GST isozyme genes on the pharma-
cokinetics of the drug.
Biol Blood Marrow Transplant 17:1222-1230, 2011 1229Pharmacogenetics of Intravenous Busulfan Clearance in Adult PatientsThe goal of pharmacogenetics is to identify genetic
differences among patients that influence treatment
responses, and devise a revised treatment strategy on
the basis of the genotype of the individual. In our
study, busufan genotyping explained 15.6% of total
variability of busulfan pharmacokinetics, which was
comparable to ABW (17.6%). Randomized, controlled
trials will be needed to determine whether this geno-
typing is valuable.
In conclusion, our results suggest that a pharmaco-
genetic approach using GST gene polymorphisms
may be useful for optimizing an i.v. busulfan dosage
scheme. Our results also highlight the importance of
including polygenic analyses and addressing inte-
ractions among isozyme genes in pharmacogenetic
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